611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Streptococcal Throat Infection Linked to Mental DisordersCognitive Decline Linked to Visual Field VariabilityRiboflavin Shows Positive Effect for Migraine in AdultsPromising Results for Drug to Fight Arthritis Linked to PsoriasisKidneys From Deceased Diabetics Might Ease Organ Shortage: StudyNew Cholesterol Fighting Meds Target Key GeneEye Problems May Be Tied to Zika, Lab Study SuggestsATS: Bronchial Thermoplasty Has Lasting Benefits for AsthmaSleepless Nights Could Pose Heart Risk DangersHospital Protocol Helps Thwart Serious InfectionZika Arrived in Florida at Least Four Different WaysKnow the Signs of Thyroid TroubleStudies Spotlight Diet, Supplements for Knee PainFunctional Interaction Seen for Dietary Carbohydrates With AMDTaking Opioids Before Knee Surgery Could Raise Pain LaterATS: First Abx Rx Doesn't Work for ~25% of Pneumonia CasesActemra Approved for Certain Blood Vessel InflammationStudy Casts Doubt on Need for Statins in the 'Healthy Old'First-Try Antibiotics Now Fail in 1 in 4 Adult Pneumonia CasesOvercrowded ERs Risky for Some Seriously Ill PatientsHigh Vitamin K1 Intake Linked to Reduced Cataract RiskPoverty Could Make Lupus Even WorseCDC: Crypto Outbreaks Linked to Pools Have Doubled Since 2014Could Cancer Drug Gleevec Help With Severe Asthma?Zika Mosquito Can Transmit Other Viruses, TooFDA OKs Kalydeco for Additional Mutations in Cystic FibrosisKalydeco Approval Widened for More Types of Cystic FibrosisAnother Step Toward Ebola ProtectionThe Water's Not Fine: U.S. Pool-Linked Infection Doubles in 2 YearsJust 2 Weeks on the Couch Can Trigger Body's DeclineGene Therapy Might Someday Mend Badly Broken Bones'Healthy Obese' May Be a MythNo Evidence Steroids Benefit Symptomatic Knee OsteoarthritisHeart Attack Risk Spikes After Respiratory Infection, Study FindsFor Inflamed Pancreas, Eating Right Away May Be Best MedicineFindings Support More Targeted Approach to Cholesterol ScreensHouston, You Have a 'Superbug'Forget Steroid Shots for Long-Term Relief of Arthritic KneesFDA Approves New Device to Treat Esophageal AtresiaMany U.S. Travelers Skip Measles Shots, Despite Infection RiskMany Under 40 May Not Need Regular Cholesterol Checks: StudyNew Device Approved for Esophageal Birth DefectACP: Recommendations Updated for Low Bone Density TreatmentMosquito-Borne Illnesses May Not Be Limited to TropicsArthroscopy for Degenerative Knees Deemed Seldom EffectiveBioengineered Intraabdominal Endocrine Pancreas FeasibleAllergies Getting Worse? Blame Climate ChangeA 2nd Life for Risky Kidney Transplants?Blood Vessel-Clearing Procedure Riskier on Weekends: StudyMultidrug-Resistant TB Set to Increase Through 2040
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves 1st New Drug for ALS in Decades

HealthDay News
by -- Robert Preidt
Updated: May 8th 2017

new article illustration

MONDAY, May 8, 2017 (HealthDay News) -- The first new drug to treat amyotrophic lateral sclerosis (ALS) in more than 20 years has been approved by the U.S. Food and Drug Administration.

Radicava (edaravone) is taken intravenously daily for 14 days, followed by 14 days without the drug. Subsequent treatment cycles consist of treatment for 10 out of 14 days, followed by 14 days without the drug.

"After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States," Dr. Eric Bastings, deputy director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option," Bastings added.

The very first ALS drug, riluzole, was approved by the FDA in 1995.

ALS, also known as Lou Gehrig's disease, is a progressive, always fatal neurological disease that destroys the nerve cells that control voluntary muscles, including those used for chewing, walking, breathing and talking. Most patients die from respiratory failure within three to five years after symptoms begin.

About 12,000 to 15,000 Americans have ALS, according to the U.S. Centers for Disease Control and Prevention.

The FDA's approval of Radicava was based on a six-month clinical trial in Japan that included 137 patients who received either the drug or an inactive placebo, the agency said Friday. After 24 weeks, patients taking the drug had less decline in physical functioning than those taking the placebo.

The most common side effects among patients taking the drug were bruising and walking problems, the findings showed.

"Radicava is also associated with serious risks that require immediate medical care, such as hives, swelling or shortness of breath, and [life-threatening] allergic reactions to sodium bisulfite, an ingredient in the drug," the agency said in the news release.

One ALS expert said the approval gives patients a desperately needed option.

"The effect is modest but significant," Dr. Neil Shneider, director of the Eleanor and Lou Gehrig ALS Center at Columbia University Medical Center in New York City, told The New York Times. "I'm very happy, frankly, that there is a second drug approved for ALS."

But Shneider stopped short of saying he would actually recommend it to his ALS patients, because the intravenous drug is difficult and time-consuming to administer.

"If it were a pill and easily administered, I'd be less reluctant to use it," he told the newspaper.

Shneider added that the drug will not make patients feel better or stronger; it can only slow the decline of the devastating disease.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on ALS.